Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2005-12-16
- Lead Sponsor
- Mylan Bertek Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT00200525
Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2005-12-16
- Lead Sponsor
- Mylan Bertek Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT00200512
- Locations
- 🇬🇧
The Morriston Hospital, Swansea, United Kingdom
🇬🇧Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom
A Pilot Study Comparing Nebivolol and Atenolol and Its Effects With Exercise in Patients With Mild to Moderate Hypertension
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2005-12-16
- Lead Sponsor
- Mylan Bertek Pharmaceuticals
- Target Recruit Count
- 110
- Registration Number
- NCT00200421
- Locations
- 🇺🇸
Mylan Pharmaceuticals Inc., Morgantown, West Virginia, United States
A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive Patients
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2005-12-16
- Lead Sponsor
- Mylan Bertek Pharmaceuticals
- Target Recruit Count
- 845
- Registration Number
- NCT00200499
- Locations
- 🇺🇸
Mylan Pharmaceuticals Inc., Morgantown, West Virginia, United States
A Study Evaluating the Effects of Nebivolol on Blood Pressure in Hypertensive Patients
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2005-09-20
- Lead Sponsor
- Mylan Bertek Pharmaceuticals
- Target Recruit Count
- 825
- Registration Number
- NCT00200460
- Locations
- 🇺🇸
Mylan Pharmaceuticals Inc., Morgantown, West Virginia, United States
A Study of the Safety and Efficacy of Nebivolol in Hypertensive Patients
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2005-09-20
- Lead Sponsor
- Mylan Bertek Pharmaceuticals
- Target Recruit Count
- 800
- Registration Number
- NCT00200473
- Locations
- 🇺🇸
Mylan Pharmaceuticals Inc., Morgantown, West Virginia, United States
A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2005-09-20
- Lead Sponsor
- Mylan Bertek Pharmaceuticals
- Target Recruit Count
- 600
- Registration Number
- NCT00200434
- Locations
- 🇺🇸
Mylan Pharmaceuticals Inc., Morgantown, West Virginia, United States
A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2005-09-12
- Lead Sponsor
- Mylan Bertek Pharmaceuticals
- Target Recruit Count
- 260
- Registration Number
- NCT00158093
- Locations
- 🇺🇸
SFBC International, Inc., Miami, Florida, United States
Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2005-09-14
- Lead Sponsor
- Mylan Bertek Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT00145236
- Locations
- 🇺🇸
Mylan Pharmaceuticals Inc., Morgantown, West Virginia, United States
A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2005-09-05
- Lead Sponsor
- Mylan Bertek Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT00145171
© Copyright 2024. All Rights Reserved by MedPath